EGFR

[Turning Point Therapeutics] Turning Point Therapeutics, Inc. announced that the company has received clearance from the FDA for the company’s Investigational New Drug application for the combination of elzovantinib and aumolertinib in EGFR mutant MET-amplified advanced non-small cell lung cancer.

[Cell Death Discovery] Scientists investigated the effects of hCAP18/LL-37 on hepatocellular carcinoma (HCC) in vitro and in vivo. Results showed that hCAP18/LL-37 overexpression significantly promoted the proliferation of cultured HCC cells and the growth of PLC/PRF-5 xenograft tumor.

[Cell Death & Disease] Scientists indicated that NONO enhanced nuclear epidermal growth factor receptor (EGFR)-mediated tumorigenesis and may be a potential therapeutic target for TNBC patients with nuclear EGFR expression.

[Cell Reports] The authors found that CDC42 loss initiated in the intestinal stem cell caused a drastic hyperproliferation of transit amplifying cells and disrupted epithelial polarity.

[BioAtla, Inc. (PR Newswire, Inc.)] BioAtla, Inc. announced that it has entered into a clinical collaboration with Bristol Myers Squibb to investigate BioAtla's two lead CAB-ADC candidates, BA3011 and BA3021, in combination with Bristol Myers Squibb's anti-PD-1 therapy nivolumab.

[Environmental Toxicology] Vemurafenib-resistant A375.S2 cells were established, and the functional mechanism of the epidermal growth factor receptor (EGFR), serine–threonine kinase, and the extracellular signal-regulated kinase signaling induced by curcumin was investigated in A375.S2/VR cells in vitro.